VEEV stock forecast, quote, news & analysis
Veeva is the global leading supplier of cloud-based software solutions for the life sciences industry... Show more
Veeva Systems (VEEV) Stock Analysis: Life Sciences Cloud Leader Awaits Key Earnings Update
Key Takeaways
- Veeva Systems continues to expand its footprint in life sciences with new customer commitments to Vault CRM and Quality Cloud solutions.
- The company’s upcoming fiscal first-quarter earnings release on June 3, 2026, is expected to draw significant investor attention amid options-implied volatility.
- Addition to the S&P 500 in early May provided a notable catalyst, boosting visibility and index-related inflows.
- Analyst sentiment remains largely positive despite select rating adjustments earlier in the year, with consensus price targets indicating meaningful upside potential.
- Strong fiscal 2026 results, including 16% revenue growth, underscore Veeva’s established position in industry-specific cloud software.
Current Market Snapshot
In recent weeks, Veeva Systems shares have reflected a mix of index-driven momentum and anticipation surrounding quarterly results. The stock has shown resilience within the healthcare technology sector, supported by ongoing customer expansions and broader adoption of its cloud platforms. Trading activity has remained influenced by sector rotation and macroeconomic sentiment toward growth-oriented software names, while the company maintains a solid balance sheet and recurring revenue profile typical of its subscription-based model.
Trending AI Robots
Tickeron’s Trending AI Robots page highlights a curated selection of high-performing AI trading bots optimized for prevailing market conditions. While Tickeron offers hundreds of AI Trading Bots capable of trading thousands of different tickers, only those demonstrating the strongest alignment with current trends, risk parameters, and performance metrics earn placement in this featured section. Available bots span a wide range of trading styles, strategies, timeframes, and statistical profiles, allowing investors to explore options suited to various objectives. For more details on these automated strategies, visit Trending AI Robots.
Recent Developments Driving VEEV Price Action
Early May brought a significant structural catalyst when Veeva Systems was added to the S&P 500, replacing another company following an acquisition. The inclusion, effective May 7, 2026, triggered immediate buying from index funds and passive investors, resulting in a sharp price advance of approximately 10-11% in after-hours and premarket trading. This move enhanced liquidity and visibility for the stock while aligning it with broader market benchmarks.
On May 13, the company announced it would release fiscal 2027 first-quarter results after market close on June 3, 2026, followed by a conference call. Analysts project earnings per share of $2.13 on revenue of roughly $857.7 million, reflecting continued double-digit growth expectations. Options data suggest the shares could experience a move of around 7.6% following the report, underscoring elevated market anticipation.
Customer momentum remained positive throughout the period. On May 27, Teva Pharmaceuticals announced a global commitment to Veeva Vault CRM, strengthening the platform’s penetration among major pharmaceutical players. The following day, contract development and manufacturing organization Kindeva disclosed its adoption of Veeva Quality Cloud, including QualityDocs, QMS, Training, and LearnGxP modules, to unify quality operations across its manufacturing network and support scalability.
These operational updates reinforced investor confidence in Veeva’s ability to secure long-term contracts in a competitive life sciences software market. Earlier analyst actions, including a downgrade by Citigroup in April, had tempered sentiment temporarily, yet the overall consensus remains constructive, with most firms maintaining Buy or Outperform ratings and average price targets well above recent trading levels. The combination of index inclusion, upcoming earnings, and fresh customer wins has shaped recent price behavior and sentiment.
2026 Outlook and Key Factors to Monitor
Looking ahead through 2026, Veeva Systems is positioned to benefit from sustained demand for specialized cloud solutions in the life sciences industry, particularly around commercial, quality, and regulatory workflows. Continued expansion of Vault CRM among top pharmaceutical companies and broader adoption of Quality Cloud by manufacturers represent core growth avenues. Investors will closely track the pace of new customer wins, existing contract renewals, and any updates on artificial intelligence-enhanced features within the platform suite.
Macroeconomic factors, including healthcare spending trends and regulatory environments affecting drug development and manufacturing, could influence demand. Competitive dynamics in the vertical software space and the company’s ability to maintain high retention rates will also warrant attention. With fiscal 2027 guidance already outlined and the first-quarter report imminent, subsequent updates on revenue mix, operating margins, and long-term targets will provide further clarity on strategic execution.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
VEEV's Stochastic Oscillator remains in oversold zone for 7 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where VEEV advanced for three days, in of 281 cases, the price rose further within the following month. The odds of a continued upward trend are .
Bearish Trend Analysis
The 10-day RSI Indicator for VEEV moved out of overbought territory on June 02, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on June 11, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on VEEV as a result. In of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for VEEV turned negative on June 10, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at .
VEEV moved below its 50-day moving average on June 10, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for VEEV crossed bearishly below the 50-day moving average on June 18, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In of 15 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VEEV declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
VEEV broke above its upper Bollinger Band on May 29, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.406) is normal, around the industry mean (7.367). P/E Ratio (27.156) is within average values for comparable stocks, (49.962). Projected Growth (PEG Ratio) (0.691) is also within normal values, averaging (1.152). Dividend Yield (0.000) settles around the average of (0.046) among similar stocks. P/S Ratio (7.704) is also within normal values, averaging (5.631).
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. VEEV’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VEEV’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 99, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a provider of industry-specific, cloud-based software solutions for the life sciences industry
Industry ServicestotheHealthIndustry